Physicochemical Properties
| Molecular Formula | C118H215N10O28P |
| Molecular Weight | 2252.99 |
| Appearance | Typically exists as solids at room temperature |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | IL-6 TLR4 NOD2 |
| ln Vitro | The activity of RC529-MDP (9.3 μM, 20 h) is dependent on TLR4 and NOD2 signaling pathways[1]. RC529-MDP (conjugate) increased the proportion of CD80 and CD86 cells in Raw264.7 cells by 1.7 times compared with RC529 + MDP (mixture), and effectively promoted the maturation of antigen presenting cells (APCs)[1]. |
| ln Vivo | The RC529-MDP conjugate increased IL-6 levels in mice by 6.8-fold, resulting in a strong synergistic effect[1]. RC529-MDP (22.53 μg, ip) enhanced humoral immunity in the mouse model and also enhanced the levels of IgG subtypes (IgG1, IgG2a, IgG2b)[1]. In the mouse model where RC529-MDP (22.53 μg, sc) and OVA were injected simultaneously, adaptive humoral immunity was rapidly activated, the number of cytokine-secreting T cells increased, and strong cellular immunity was generated[1]. RC529-MDP (22.53 μg) increased the proportion of central memory T cells (Tcm) and produced a memory response[1]. |
| Animal Protocol |
Animal/Disease Models: The mice were injected subcutaneously (S.C.) with the RC529-MDP and model antigen ovalbumin (OVA)[1] Doses: 22.53 μg Route of Administration: Subcutaneous injection (s.c.) on days 1, 15, 29 Experimental Results: Induced high levels of OVA-specific IgG, and the levels of IgG subtypes were increased. Induced a 1.3-fold and 3.3-fold increase in the proportion of TNF-α and IFN-γ double-positive secreting CD4+ T and CD8+ T cells compared with RC529 + MDP. Induced the proportion of central memory T cells (Tcm) of CD8+ and CD4+ cells to increase by 2.7 and 1.2 times compared with RC529 + MDP. Animal/Disease Models: BALB/c mouse[1] Doses: 22.53 μg Route of Administration: Intraperitoneal injection (i.p.) Experimental Results: Bound to RC529-MDP-induced OVA-specific IgG 2.0 times higher than that induced by RC529 + MDP without binding. |
| References |
[1]. Dong Ding, et al. Synergistic immune augmentation enabled by covalently conjugating TLR4 and NOD2 agonists. Eur J Med Chem. 2024 Aug 26:278:116792. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.4439 mL | 2.2193 mL | 4.4385 mL | |
| 5 mM | 0.0888 mL | 0.4439 mL | 0.8877 mL | |
| 10 mM | 0.0444 mL | 0.2219 mL | 0.4439 mL |